References
Rossi JG, Bernasconi AR, Alonso CN et al (2012) Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am J Hematol 87:890–897. doi:10.1002/ajh.23266
Armstrong SA, Staunton JE, Silverman LB et al (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30:41–47. doi:10.1038/ng765
Dorantes-Acosta E, Pelayo R (2012) Lineage switching in acute Leukemias: a consequence of stem cell plasticity? Bone Marrow Res 2012:1–18. doi:10.1155/2012/406796
Batlevi CL, Matsuki E, Brentjens RJ, Younes A (2015) Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 13:25–40. doi:10.1038/nrclinonc.2015.187
Aldoss I, Bargou RC, Nagorsen D et al (2017) Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors. Leukemia 31:777–787. doi:10.1038/leu.2016.391
Gardner R, Wu D, Cherian S et al (2016) Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127:2406–2410
Lin S, Luo RT, Ptasinska A et al (2016) Instructive role of MLL-fusion proteins revealed by a model of t(4;11) pro-B acute lymphoblastic leukemia. Cancer Cell 30:737–749. doi:10.1016/j.ccell.2016.10.008
Zoghbi A, zur Stadt U, Winkler B et al (2017) Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement: ZOGHBI et al. Pediatr Blood Cancer:e26594. doi:10.1002/pbc.26594
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Informed consent
Informed consent was obtained from the patient described.
Conflict of interest
The authors declare that there are no conflicts of interest.
Rights and permissions
About this article
Cite this article
Balducci, E., Nivaggioni, V., Boudjarane, J. et al. Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. Ann Hematol 96, 1579–1581 (2017). https://doi.org/10.1007/s00277-017-3050-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-017-3050-6